<?xml version="1.0" encoding="UTF-8"?><rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0" xmlns:cc="http://cyber.law.harvard.edu/rss/creativeCommonsRssModule.html">
    <channel>
        <title><![CDATA[Stories by Harsha Doddihal on Medium]]></title>
        <description><![CDATA[Stories by Harsha Doddihal on Medium]]></description>
        <link>https://medium.com/@doddyh?source=rss-9dec98090e3f------2</link>
        <image>
            <url>https://cdn-images-1.medium.com/fit/c/150/150/0*N0eZ_lJGhr38O7nI.jpg</url>
            <title>Stories by Harsha Doddihal on Medium</title>
            <link>https://medium.com/@doddyh?source=rss-9dec98090e3f------2</link>
        </image>
        <generator>Medium</generator>
        <lastBuildDate>Sat, 21 Nov 2026 16:01:57 GMT</lastBuildDate>
        <atom:link href="https://medium.com/@doddyh/feed" rel="self" type="application/rss+xml"/>
        <webMaster><![CDATA[yourfriends@medium.com]]></webMaster>
        <atom:link href="http://medium.superfeedr.com/" rel="hub"/>
        <item>
            <title><![CDATA[Revealing the Cosmos: Astrophysics Driven by Giant Projects, Global Collaboration, and Overcoming…]]></title>
            <link>https://doddyh.medium.com/revealing-the-cosmos-astrophysics-driven-by-giant-projects-global-collaboration-and-overcoming-0df7ed520689?source=rss-9dec98090e3f------2</link>
            <guid isPermaLink="false">https://medium.com/p/0df7ed520689</guid>
            <category><![CDATA[space]]></category>
            <category><![CDATA[astronomy]]></category>
            <category><![CDATA[cosmos]]></category>
            <dc:creator><![CDATA[Harsha Doddihal]]></dc:creator>
            <pubDate>Fri, 23 May 2025 01:14:46 GMT</pubDate>
            <atom:updated>2025-05-23T01:14:46.266Z</atom:updated>
            <content:encoded><![CDATA[<h2>Revealing the Cosmos: Astrophysics Driven by Giant Projects, Global Collaboration, and Overcoming Modern Challenges</h2><p>Lausanne, Switzerland – Exploring the fundamental questions about our place in the universe requires not only brilliant minds but also colossal, costly, and increasingly complex infrastructure, often built through extensive international collaboration. This was a central theme addressed by Professor Jean-Paul Kneib from EPFL Lausanne during a recent talk at an IMD alumni event, titled “Revealing The Mysteries of The Universe”.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*AP3n4Ur-oHh-VCZblUTi_w@2x.jpeg" /></figure><p>Professor Kneib outlined the driving forces behind modern astrophysics, detailing the infrastructure needed, the challenges faced, and the benefits derived from these ambitious scientific endeavours. He emphasized that answering the universe’s big questions – such as the search for life, the nature and origin of the universe, its expansion, and the composition of dark matter and dark energy – necessitates looking at the sky with powerful tools.</p><p>Probing Cosmic Mysteries</p><p>Astrophysics seeks to answer profound questions: Is Earth the only planet with intelligent life?. What is the universe made of, why is it here, and when did it start?. We know the universe is expanding, a discovery made by Hubble, and more recently, we’ve learned this expansion is accelerating, attributed to a mysterious force called dark energy. The vast majority of a galaxy’s mass, about 80%, is made of something we call dark matter, whose nature is currently unknown. Black holes, once thought to be confined to science fiction movies, are now known to exist everywhere in the universe, including supermassive ones at the centre of galaxies like our own Milky Way. We also know that almost every star likely hosts planets, opening up possibilities for life beyond Earth. Observing distant objects means looking back in time, allowing astronomers to perform “archaeology of the universe”.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*5lHJ4pyq6iTVviIiPuMksA@2x.jpeg" /></figure><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*brrikQf_Rl8ZMX_35Atijw@2x.jpeg" /></figure><p>The Essential Infrastructure: Giants on Earth and in Space</p><p>To peer into these mysteries, astronomers rely on diverse and large instruments, primarily telescopes. Different types of telescopes are needed because they observe different forms of light or phenomena across the electromagnetic spectrum – from radio waves to gamma rays, plus gravitational waves. Each wavelength reveals different information.</p><p>Larger telescopes are crucial for collecting more light, allowing the observation of faint, distant objects, and for achieving sharper images. While ground-based optical telescopes are affected by the Earth’s atmosphere, limiting sharpness, space telescopes like Hubble and James Webb Space Telescope (JWST) operate above this distortion, providing incredibly crisp images. Observing at wavelengths blocked by the atmosphere, such as X-rays, ultraviolet light, and some infrared or gamma rays, also requires space-based observatories. Space missions, even small ones, can cost hundreds of millions or billions of dollars.</p><p>However, ground-based telescopes remain vital, especially radio telescopes which require vast collecting areas and can achieve extremely high resolution by combining signals from widely separated dishes (interferometry).</p><p>Professor Kneib highlighted several current and future giant projects. Among them are:</p><p>•	The Extremely Large Telescope (ELT): Under construction by the European Southern Observatory (ESO) in Chile, this optical telescope will have a 39-metre primary mirror, made of 798 hexagonal segments, and is expected to see first light around 2029. It is currently the largest optical telescope being built.</p><p>•	The Square Kilometre Array (SKA): An intergovernmental organization building the world’s largest radio telescope facility across sites in South Africa and Western Australia. Its numerous antennas will cover a massive area and produce unprecedented amounts of data, allowing studies of cosmic magnetism and the early universe.</p><p>•	Gravitational Wave Detectors: Instruments like LIGO (USA), Virgo (Italy), and KAGRA (Japan) work together to detect ripples in spacetime caused by violent events like merging black holes or neutron stars. Future projects like the proposed underground Einstein Telescope (primarily a European effort) and the space-based Lisa mission are planned to detect gravitational waves from even further away and from different types of sources (larger black holes for Lisa).</p><p>•	Mapping Surveys: Projects like the Dark Energy Survey Instrument (DESI) use robotic systems on telescopes to quickly measure the positions and properties of millions of galaxies, creating 3D maps of the universe to study dark energy. Future surveys are planned by different international consortia.</p><p>The cost of these facilities scales significantly with size, especially for space telescopes. A large ground telescope can cost around a billion dollars, while a major space telescope can cost upwards of 10 billion dollars. This massive scale and expense are why single universities or even single countries often cannot undertake them alone.</p><p>The Indispensable Role of International Collaboration</p><p>The sheer scale and cost of modern astronomical infrastructure make large international projects essential. Intergovernmental organizations like ESO (with 16 member countries) and the SKA Observatory (involving countries like the UK, Australia, South Africa, Italy, China, and India) provide a model for successfully building and operating these massive facilities. Contributions from member countries, often proportional to their GDP, fund these long-term visions. Space agencies like the European Space Agency (ESA), a collaboration of 23 European countries plus others, also rely heavily on international partnerships, including with NASA (USA), JAXA (Japan), and China, to fund and build complex space telescopes. Gravitational wave detection networks require correlating signals from instruments in different countries to confirm detections. These collaborations are seen as necessary for achieving the world’s leading capabilities.</p><p>Navigating the Challenges of the 21st Century</p><p>Despite the scientific progress, astrophysics faces significant challenges.</p><p>•	Big Data: Modern telescopes generate enormous volumes of data. The SKA project alone is projected to produce 700 petabytes per year, potentially exceeding the data volume on the entire internet today. Handling, processing, and transferring this data, especially from remote observatory sites in the Southern Hemisphere to researchers in the Northern Hemisphere, requires massive computing power (supercomputing is a major energy cost) and presents a significant logistical hurdle.</p><p>•	Satellite Constellations: The rapid increase in satellite launches, particularly large constellations planned to number in the hundreds of thousands, poses a severe threat to astronomical observation. They cause light pollution, interfering with optical telescopes by leaving streaks across images. They also emit radio signals, interfering with the “quiet sky” needed for radio astronomy, especially at low frequencies. This trend could fundamentally change the view of the night sky, potentially making the dark skies many people have experienced a thing of the past.</p><p>•	Securing Funding: Funding for these large, long-term projects remains a constant challenge. While governments, space agencies, intergovernmental organizations, universities, and some private donors contribute, balancing costs and securing commitment over decades is difficult.</p><p>•	Sustainability: Large observatories require significant energy and resources. Astronomers are increasingly aware of their environmental footprint and are seeking ways to minimize it, for instance, by integrating renewable energy sources at remote sites.</p><p>•	Local Interference: Even after building observatories in remote, ideal locations, they can face threats from nearby industrial developments that could produce dust, light, or radio interference.</p><p>Funding, Leadership, and the Worldwide Community</p><p>Funding for astrophysics primarily originates from governments, space agencies, and intergovernmental bodies. Universities and private donors also play a role, particularly in countries like the USA. Leadership in the field has historically been held by the USA and Europe. However, Professor Kneib noted that Asia, particularly China, is rapidly advancing and is expected to become a significant leader in the future. The field is supported by a worldwide scientific community known for its collaborative spirit.</p><p>The Importance and Sharing of Knowledge</p><p>Ultimately, astrophysics is crucial for expanding our understanding of the universe and our place within it. The scientific community is driven by innovation, engineering, and computing, constantly pushing technological boundaries. Professor Kneib also highlighted the importance of communicating this science to the public, mentioning exhibitions that share the wonders of the cosmos with a wider audience. Despite the challenges, the quest to reveal the mysteries of the universe continues, fueled by curiosity, collaboration, and cutting-edge technology.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=0df7ed520689" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Did A&W’s 1/3 Pound Burger Fail Due to Math Misunderstandings?]]></title>
            <link>https://doddyh.medium.com/did-a-ws-1-3-pound-burger-fail-due-to-math-misunderstandings-2e2e69cb35b8?source=rss-9dec98090e3f------2</link>
            <guid isPermaLink="false">https://medium.com/p/2e2e69cb35b8</guid>
            <category><![CDATA[marketing]]></category>
            <category><![CDATA[mcdonalds]]></category>
            <dc:creator><![CDATA[Harsha Doddihal]]></dc:creator>
            <pubDate>Wed, 30 Apr 2025 20:41:52 GMT</pubDate>
            <atom:updated>2025-04-30T20:41:52.680Z</atom:updated>
            <content:encoded><![CDATA[<p>In the 1980s, A&amp;W launched a 1/3 pound burger to compete with McDonald’s popular Quarter Pounder, but the burger flopped. A common story claims it failed because Americans misunderstood fractions, believing a 1/4 pound was larger than a 1/3 pound. But is this tale fact or fiction? A Reddit thread from April 2022 on r/IsItBullshit, posted by u/FlameDragoon933, sparked a lively debate about this fast-food legend, garnering 896 votes and 245 comments.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/540/1*DdbyWDwiFqrI_L6askG8bw@2x.jpeg" /></figure><figure><img alt="" src="https://cdn-images-1.medium.com/max/540/1*7OwuTvBF8_is85DBsvp9aQ@2x.jpeg" /></figure><p>The story stems from reports that A&amp;W’s focus groups revealed customers thought the 1/3 pound burger was smaller than McDonald’s 1/4 pounder due to the larger denominator (4 versus 3). Some Reddit users lent credence to this, citing anecdotes from the era. One user shared their experience working at Burger King in 1975, noting customers frequently complained about paying more for a “smaller” 1/3 pound burger. Another recalled people at an A&amp;W stand in their hometown’s mall asking why the “third pound” cost more than a “quarter pound,” suggesting confusion among adult customers.</p><p>However, skepticism abounds. Critics on the thread argued the failure was more about taste, branding, or McDonald’s market dominance. One commenter pointed out that McDonald’s burgers might have simply tasted better or felt more familiar to consumers, dismissing the fraction confusion as “the dumbest argument ever.” Another suggested A&amp;W’s marketing misstep – calling it a “third-pounder” instead of emphasizing its 32% larger size – contributed to the flop. The term “quarter pounder” itself, used by McDonald’s, avoids the fractional notation that may have tripped up A&amp;W’s campaign.</p><p>Evidence for the math confusion theory is thin, often tied to a single source: a book by an A&amp;W owner later convicted of price-fixing, casting doubt on its reliability. Meanwhile, cultural factors, like the unwieldy sound of “third-pounder” compared to the snappy “quarter pounder,” likely played a role. As one user noted, fractions are less common in metric systems elsewhere, making the U.S.’s use of pounds and ounces ripe for misunderstanding.</p><p>Ultimately, the Reddit discussion leans toward calling the story exaggerated but not entirely bullshit. While some customers may have been baffled by fractions, A&amp;W’s failure likely stemmed from a mix of marketing missteps, McDonald’s dominance, and consumer preferences – not just a national math meltdown. The legend persists as a cautionary tale of how perception can outweigh reality in the fast-food wars.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=2e2e69cb35b8" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Etymology & History Learning]]></title>
            <link>https://doddyh.medium.com/etymology-history-learning-030fbc9d2aee?source=rss-9dec98090e3f------2</link>
            <guid isPermaLink="false">https://medium.com/p/030fbc9d2aee</guid>
            <category><![CDATA[learning]]></category>
            <category><![CDATA[history]]></category>
            <category><![CDATA[etymology]]></category>
            <category><![CDATA[french]]></category>
            <category><![CDATA[english]]></category>
            <dc:creator><![CDATA[Harsha Doddihal]]></dc:creator>
            <pubDate>Tue, 25 Feb 2025 11:02:22 GMT</pubDate>
            <atom:updated>2025-02-25T11:02:22.360Z</atom:updated>
            <content:encoded><![CDATA[<p>English is a successful language not only because the “Sun Never Set In The British Empire” but also because it adapts, borrows and keeps puritans in check!</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*zjT5K60GGHrJ2mDneeKaig.jpeg" /></figure><p>English words have etymological roots in Latin and Greek. English has words from French too. In 1066 AD, the Duke of Normandy (French-there was no country at that time called France!) defeated English army under King Harold. The <a href="https://www.csun.edu/~sk36711/WWW2/engl443/history_1066-1413.htm"><strong>Plantagenet Dynasty</strong></a><strong> </strong>ruled for couple of hundred years.</p><p>This has also lead to lot of French words being adopted by English. The pronunciation is a different matter.</p><p>A google search or AI search will give the complete list, I am referencing one site ,</p><blockquote>“<a href="https://www.pimsleur.com/blog/french-influence-on-the-english-language/">Did you know that nearly 45% of all English words are of French origin? That’s nearly 80,000 words fused together through war, peace, diplomacy, royal marriages, and popular culture”.</a></blockquote><p>Few words of interest from French &amp; English!</p><p>Copain means boyfriend, Copine means girlfriend and Copains means friends (as per Google translate).</p><p><a href="https://romanlangpassion.com/word-of-the-day-copain-copine/">The origin of the word can be traced back to the Latin phrase “cum panem“</a>, which means “with bread“. This phrase was used in medieval times to describe people who ate meals together, often breaking bread or sharing a loaf.</p><p>pain=bread in French</p><p>And the English word “Companion” becomes easier to understand. A companion is someone who breaks bread with another.</p><p>RSVP which we all use stands for Répondez s’il vous plaît, which is please respond.</p><p>Petite learning for today! Petite is from French :).</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=030fbc9d2aee" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Prediction of checkpoint inhibitor immunotherapy efficacy]]></title>
            <link>https://doddyh.medium.com/prediction-of-checkpoint-inhibitor-immunotherapy-efficacy-af931ff73859?source=rss-9dec98090e3f------2</link>
            <guid isPermaLink="false">https://medium.com/p/af931ff73859</guid>
            <category><![CDATA[immunotherapy]]></category>
            <category><![CDATA[healthcare]]></category>
            <category><![CDATA[innovation]]></category>
            <category><![CDATA[ai]]></category>
            <category><![CDATA[cancer]]></category>
            <dc:creator><![CDATA[Harsha Doddihal]]></dc:creator>
            <pubDate>Fri, 21 Feb 2025 08:43:27 GMT</pubDate>
            <atom:updated>2025-02-21T08:43:27.970Z</atom:updated>
            <content:encoded><![CDATA[<p>Predicting response to therapy helps patients, doctors, providers, insurers, and pharmaceutical companies. It reduces waste and improves adherence. AI / ML is being explored to predict treatment responses and they are making great strides. Recently researchers have unveiled <a href="https://www.nature.com/articles/s41591-024-03398-5"><strong>SCORPIO</strong></a>, an innovative machine learning model poised to revolutionize cancer immunotherapy. Designed to predict the efficacy of immune checkpoint inhibitors (ICIs) using routine blood tests and clinical data, SCORPIO offers a more accessible and cost-effective alternative to traditional genomic and immunologic assays.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/0*8AeO7ZDEh-S5UTO4.png" /></figure><p>The study, encompassing data from 9,745 ICI-treated patients across 21 cancer types, demonstrated SCORPIO’s superior predictive performance. Notably, it outperformed existing FDA-approved biomarkers such as tumor mutational burden (TMB) and PD-L1 staining. SCORPIO achieved a median time-dependent area under the receiver operating characteristic curve (AUC(t)) of 0.763 for predicting overall survival, compared to TMB’s 0.503. This significant advancement underscores SCORPIO’s potential to enhance patient stratification and treatment planning in diverse healthcare settings. </p><p>This development aligns with a broader trend in oncology, where machine learning models are increasingly utilized to predict immunotherapy outcomes. For instance, a 2021 study published in <em>Nature Biotechnology</em> introduced a model that integrates genomic, molecular, demographic, and clinical data to forecast ICI responses across multiple cancer types. This model also surpassed TMB in predictive accuracy, highlighting the value of multifaceted data integration in treatment planning. </p><p>Similarly, research featured in <em>Scientific Reports</em> in 2022 detailed machine learning models that identify predictors of clinical outcomes with first-line ICI therapy in advanced non-small cell lung cancer. These models utilized real-world data to achieve concordance indices of 0.672 for overall survival and 0.612 for progression-free survival, emphasizing the practical applicability of such approaches in clinical settings.</p><p>While these studies underscore the promise of machine learning in enhancing immunotherapy efficacy predictions, SCORPIO distinguishes itself by relying solely on routine blood tests and basic clinical data. This approach not only reduces the need for specialized assays but also broadens the model’s applicability, particularly in resource-limited settings. As the medical community continues to embrace artificial intelligence, SCORPIO exemplifies how leveraging readily available clinical information can lead to more personalized and effective cancer treatments.</p><h4>Deep Dive:</h4><p>Key findings:</p><p><strong>Superior Predictive Performance</strong>:</p><ul><li>SCORPIO demonstrated superior predictive performance compared to tumor mutational burden (TMB) and PD-L1 staining. Specifically, SCORPIO achieved median time-dependent area under the receiver operating characteristic curve (AUC(t)) values of 0.763 and 0.759 for predicting overall survival at 6, 12, 18, 24, and 30 months. This outperformed TMB, which showed median AUC(t) values of 0.503 and 0.543.</li><li>For predicting clinical benefit, SCORPIO achieved AUC values of 0.714 and 0.641, compared to TMB’s AUC of 0.546 and 0.573.</li></ul><p><strong>External Validation</strong>:</p><p>External validation across diverse healthcare settings, including 10 global phase 3 clinical trials and a real-world cohort from the Mount Sinai Health System (MSHS), confirmed SCORPIO’s reliability and adaptability. In these external cohorts, SCORPIO maintained robust performance in predicting ICI outcomes.</p><p><strong>Real-World vs. Clinical Trials</strong>:</p><p>SCORPIO’s performance was generally better in real-world clinical settings compared to clinical trials. For example, in bladder cancer, the median AUC(t) in real-world cohorts was 0.809, outperforming the 0.782 observed in the IMvigor211 trial. Similarly, for hepatobiliary cancer, the median AUC(t) in real-world data reached 0.746, surpassing the 0.704 reported in the IMbrave150 trial.</p><p><strong>Risk Stratification</strong>:</p><p>SCORPIO’s risk stratification grouped patients into high-, moderate-, and low-risk categories based on risk scores. This stratification significantly correlated with clinical outcomes. For instance, across tumor types, hazard ratios (HRs) for death compared to the high-risk group were 0.16 (95% CI, 0.14–0.19) for the low-risk group and 0.38 (95% CI, 0.34–0.43) for the moderate-risk group. Clinical benefit rates also varied significantly across these risk groups.</p><h4>Regulatory and Research Considerations</h4><ol><li>Regulatory Approval and Standardization: Validate SCORPIO’s clinical utility through prospective trials to seek FDA and global regulatory approval.</li><li>Comparison with Emerging Biomarkers: Future research should benchmark SCORPIO against liquid biopsy-based markers, circulating tumor DNA (ctDNA), and immune signatures. Once a coorelation is established, this can help eliminate doing liquid biopsies which are more resource intensive. Combine SCORPIO with imaging (radiomics, PET/CT scans) and molecular data for enhanced prediction accuracy.</li><li>Prospective Clinical Trials: Conduct trials comparing SCORPIO-predicted outcomes with actual patient responses.</li><li>Explainability and Transparency: Develop user-friendly interpretability tools to help clinicians understand SCORPIO’s risk scores.</li></ol><h4>Prospective Real-World Studies</h4><ul><li>Conduct multi-center prospective studies to assess SCORPIO’s impact on clinical decision-making.</li><li>Investigate cost-effectiveness and patient outcomes in healthcare settings with different resource levels.</li></ul><h4>Conclusion</h4><p>SCORPIO represents a significant advancement in predicting the efficacy of ICIs, offering a non-invasive, cost-effective, and globally accessible solution. By leveraging routine blood tests and clinical data, SCORPIO can help clinicians make more informed treatment decisions, potentially improving patient outcomes and reducing unnecessary treatment costs. As research continues, SCORPIO’s integration into clinical practice could mark a new era in precision cancer medicine.</p><p>References:</p><ul><li><a href="https://www.nature.com/articles/s41587-021-01070-8">Improved prediction of immune checkpoint blockade efficacy across multiple cancer types - Nature Biotechnology</a></li><li><a href="https://www.nature.com/articles/s41598-022-20061-6">Machine learning models for identifying predictors of clinical outcomes with first-line immune checkpoint inhibitor therapy in advanced non-small cell lung cancer - Scientific Reports</a></li></ul><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=af931ff73859" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Insights from Eli Lilly’s CEO: Innovation, Culture, and the Future of Healthcare]]></title>
            <link>https://doddyh.medium.com/insights-from-eli-lillys-ceo-innovation-culture-and-the-future-of-healthcare-c2b182dba99b?source=rss-9dec98090e3f------2</link>
            <guid isPermaLink="false">https://medium.com/p/c2b182dba99b</guid>
            <category><![CDATA[leadership]]></category>
            <category><![CDATA[pharmaceutical]]></category>
            <category><![CDATA[weight-loss]]></category>
            <category><![CDATA[innovation]]></category>
            <category><![CDATA[eli-lilly]]></category>
            <dc:creator><![CDATA[Harsha Doddihal]]></dc:creator>
            <pubDate>Thu, 20 Feb 2025 10:59:58 GMT</pubDate>
            <atom:updated>2025-02-20T11:27:56.812Z</atom:updated>
            <content:encoded><![CDATA[<p>Yesterday, I had the pleasure of listening to a conversation between Nicolai Tangen, CEO of Norges Bank Investment Management and David Ricks, the CEO of Eli Lilly, and was struck by his insights on a range of topics, from drug discovery to company culture. Below I capture few of the things which caught my attention. And amongst them, how the geographical location of Eli Lily in Indiana has worked out to its advantage.</p><iframe src="https://cdn.embedly.com/widgets/media.html?src=https%3A%2F%2Fwww.youtube.com%2Fembed%2Fxl5-ZG3X1v0%3Ffeature%3Doembed&amp;display_name=YouTube&amp;url=https%3A%2F%2Fwww.youtube.com%2Fwatch%3Fv%3Dxl5-ZG3X1v0&amp;image=https%3A%2F%2Fi.ytimg.com%2Fvi%2Fxl5-ZG3X1v0%2Fhqdefault.jpg&amp;type=text%2Fhtml&amp;schema=youtube" width="854" height="480" frameborder="0" scrolling="no"><a href="https://medium.com/media/d77dfd255f78a89ef21531f224a92b2d/href">https://medium.com/media/d77dfd255f78a89ef21531f224a92b2d/href</a></iframe><h4>Innovation in Pharmaceuticals:</h4><ol><li>Drug discovery involves identifying the right target that is causing the disease and then drugging that target with maximum effect and minimum side effects. “Picking the target is hard, and then drugging the targets is even harder”. The easy targets have all been identified ? and commercialised? Only 10–15% of all biology is known and therefore there is still lot to discover and improve.</li><li>Creating new molecules that can become medicines against known target is challenging. Either the drug isn’t good enough or the target wasn’t exactly right. The biggest cost in drug development is failure. The ROI on R&amp;D is close to zero.</li><li>Eli Lily has been able to cut down on preclinical time by half and clinical development time significantly, mostly by improvinf speed of decision making and process engineering.</li></ol><blockquote>“While as the pharmaceutical industry has price by earning ratio of 12, the PE of Eli Lily is “160”.</blockquote><p>The cost of developing a drug is 3 billion dollars. Most of this happens post phase 2 of drug development.</p><h4>GLP1 and Weight Loss Drugs</h4><p>Eli Lily had its first GLP1 in 2006 and weight loss was a positive side effect of the initial GLP1 launched.</p><p>Today GLP1’s are being studied in most hedonistic conditions. Success in smoking, opioid addiction will translate to significant lives being saved.</p><p>There is also obvious benefits on cardiovascular, neurological and renal functioning.</p><h4><strong>Company Culture and Leadership:</strong></h4><p>Curiosity and a learn-it-all culture are core to Eli Lilly’s ethos. Also having the headquarters in Indiana has helped to retain talent. This translates to better pattern recognition by key employees.</p><p>The company fosters a humanistic environment with high standards for cordiality and respect. Coffee break conversations and their impact on exchange of ideas and learning.</p><p>Fighting bureaucracy is achieved through relationships and ensuring processes work for the people, not against them. He gives good examples.</p><h4><strong>Global Perspectives:</strong></h4><p>While the drug development process is similar in the US and Europe, the adoption of technology is slower in Europe. On average there is 24 to 28 months delay in drugs becoming accessible to patients in Europe.</p><p>China’s regulatory system has improved dramatically, with a goal to be the first place for new drug launches. China has cut down the approval process timeline from 6 years to less than a year.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*ZT1YY1zd940VZ7fpzs47pw.jpeg" /></figure><p>Ricks’ emphasis on continuous learning, embracing speed, and fostering a culture of curiosity offers valuable lessons for leaders in any industry.</p><p>The podcast “In Good Company” is available on <a href="https://www.nbim.no/en/news-and-insights/podcast/">multiple platforms</a>.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=c2b182dba99b" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Diversity, Fast Learning & the Challenge of French Class]]></title>
            <link>https://doddyh.medium.com/diversity-fast-learning-the-challenge-of-french-class-e821114fc24a?source=rss-9dec98090e3f------2</link>
            <guid isPermaLink="false">https://medium.com/p/e821114fc24a</guid>
            <category><![CDATA[language-learning]]></category>
            <category><![CDATA[ultralearning]]></category>
            <category><![CDATA[french]]></category>
            <category><![CDATA[diversity]]></category>
            <category><![CDATA[learning]]></category>
            <dc:creator><![CDATA[Harsha Doddihal]]></dc:creator>
            <pubDate>Tue, 18 Feb 2025 20:16:11 GMT</pubDate>
            <atom:updated>2025-02-18T20:16:11.444Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/512/1*HxsLeupk2fj4h2ADkmUDRw.jpeg" /><figcaption>Image created with Perchance.org</figcaption></figure><p>It has been few weeks that I am attending French class. The professor is a Swiss national who spent 30 years in Thailand, bringing unique perspective to teaching. My classmates are 2 men and 5 ladies who are natives from Bosnia, Columbia, Ecuador, Eritrea, Macedonia, Serbia and Sri Lanka. English is spoken by Serbian and Sri Lankan, others have not had the chance or requirement to learn English. So, I get to hear two other languages Spanish and Slavic. Everybody is friendly but the bond is better amongst people sharing common native language. Despite our diverse backgrounds, we are all united by one goal: learning French.</p><p>Among the group, I am the least fluent in French. While my classmates converse effortlessly, I find myself listening more than speaking — which, is a silver lining. My desire to become better at “active listening’ is getting a boost, and I am trying to employ it outside the French classroom. Feedback from colleagues, friends and families 3 months from now will inform me whether I am listening better.</p><p>Honing of French verbs and pronunciation is what I am at. Progress feels slow, but I’m inspired by the concept of “Ultralearning” — a technique used by people who master new skills in record time through intense focus and immersion. I first heard about this approach from a Romanian carpenter who assembled my IKEA furniture; he swore by it for language learning.</p><p>Incidentally I came across a book related to it : “<a href="https://amzn.to/42VLP6g">Ultralearning</a>” (affiliate link) by Scott H Young. The author shares his incredible feat of completing an MIT course without ever attending MIT and learning new languages in just a few months. Neuroscience comes into play and the book expounds on those concepts.</p><p>Retrieval, feedback and retention are some concepts which are well known by most. Periodical testing of one’s knowledge to check whether we remember it or not is fundamental to learning. To progress, feedback is required and that’s the reason classroom teaching and a network of learners/experts helps.</p><p>Spaced repetition/ revisions and applying the learning in practical setting further cements the learning.</p><p>The book starts with “Meta-Learning”, a terminology now used in context of Machine Learning. “Meta-Learning” is crucial as it also concerns about how we humans learn. Learning about learning is “Meta-Learning”.</p><p>Some learn by listening, some by watching / visualising, some by reading and almost all by “doing”. A combination of the above is required to learn effectively but individuals and children have their preference and knowing that helps to learn effectively.</p><p>Peter Drucker had addressed this for executives in his classic <a href="https://amzn.to/4i4mPOo">“Managing Oneself” </a>(affiliate link). Knowing oneself and how one’s boss, colleagues and team members learn or do their job helps one perform better.</p><p>I am not an ultralearner yet and my focus is not just on learning French but I intend to do better.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=e821114fc24a" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[People-Centred Care in Oncology]]></title>
            <link>https://doddyh.medium.com/people-centred-care-in-oncology-a1c2bd05e75e?source=rss-9dec98090e3f------2</link>
            <guid isPermaLink="false">https://medium.com/p/a1c2bd05e75e</guid>
            <category><![CDATA[treatment]]></category>
            <category><![CDATA[holistic-health]]></category>
            <category><![CDATA[cancer]]></category>
            <category><![CDATA[world-cancer-day]]></category>
            <category><![CDATA[oncology]]></category>
            <dc:creator><![CDATA[Harsha Doddihal]]></dc:creator>
            <pubDate>Tue, 04 Feb 2025 22:43:00 GMT</pubDate>
            <atom:updated>2025-02-04T22:43:00.722Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*lT4NGWUV9mI4QfGYBByUqg.jpeg" /></figure><h4>Introduction</h4><p>People-centred care in oncology represents a significant shift from traditional disease-focused care to a more holistic approach that prioritises the needs, preferences, and values of patients and their families. This model of care emphasises collaboration, connection, and community involvement, recognising that cancer treatment is not just about curing the disease but also about improving the quality of life for patients. By reorienting healthcare around people instead of diseases, people-centred care seeks to provide more compassionate, effective, and efficient oncology services.</p><h4>Reorienting Healthcare Around People</h4><p>People-centred care in oncology redefines the patient-provider relationship by placing the patient at the centre of the care process. This approach acknowledges that every patient is unique, with distinct needs, concerns, and preferences. For instance, the V<a href="https://jamanetwork.com/journals/jamaoncology/fullarticle/2551984">alues and Options in Cancer Care (VOICE) trial</a> demonstrated that patient-centred communication could improve the quality of interactions between patients and oncologists. By fostering healing relationships, exchanging information, and responding to emotions, oncologists can help patients make informed decisions that align with their values and goals.</p><h4>The Importance of Social Ties</h4><p>People-centred care also recognises the crucial role of social ties in the well-being of patients. Social support from family, friends, and community members can significantly impact a patient’s mental and physical health. For example, studies have shown that strong social connections can buffer stress, improve adherence to treatment, and enhance overall health outcomes. <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC10566299/">Programs like the NCI-CONNECT initiative</a>, which brings together patients with rare central nervous system tumors for support and education, exemplify how involving social networks can improve patient experiences and outcomes.</p><h4>Informing and Engaging Patients</h4><p>Informing and engaging patients is a cornerstone of people-centred care. Patients who are well-informed about their treatment options, prognosis, and potential side effects are better equipped to participate in shared decision-making. For example, the Cancer Moonshot Biobank not only collects biospecimens for research but also provides comprehensive tumor profiling results to patients and their physicians. This information can guide treatment decisions and improve patient care. Additionally, educational resources and support groups, such as those offered by MD Anderson Cancer Center, empower patients and their families to make informed choices and manage their health.</p><h4>Benefits of People-Centred Care</h4><p>The benefits of people-centred care in oncology are manifold. Patients often report higher satisfaction with their care, improved quality of life, and better adherence to treatment plans. Healthcare providers also benefit from more meaningful interactions with patients, leading to increased job satisfaction and reduced burnout. Moreover, this approach can lead to more efficient use of resources by focusing on the most effective treatments and minimising waste.</p><h4>Conclusion</h4><p>People-centred care in oncology represents a transformative approach that prioritises the needs and preferences of patients. By reorienting healthcare around people, recognising the importance of social ties, and actively informing and engaging patients, this model of care aims to provide more compassionate, effective, and efficient services. As healthcare systems continue to evolve, embracing people-centred care can lead to better outcomes for patients and a more resilient healthcare system.</p><p>References:</p><ul><li><a href="https://www.worldcancerday.org/the-campaign/what-people-centred-care">What is people centred care?</a></li><li><a href="https://www.cancer.gov/research/key-initiatives/moonshot-cancer-initiative/implementation/patient-engagement">Direct Patient Engagement Network - Cancer Moonshot Recommendation</a></li><li><a href="https://www.cancer.gov/about-cancer/coping/adjusting-to-cancer/communication-hp-pdq#section_3.21">Communication in Cancer Care (PDQ®)</a></li><li><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC10566299/">Stand by Me: Social Ties and Health in Real-Time</a></li><li><a href="https://www.cancer.gov/research/key-initiatives/moonshot-cancer-initiative/implementation/patient-engagement">Direct Patient Engagement Network - Cancer Moonshot Recommendation</a></li><li><a href="https://www.mdanderson.org/patients-family/diagnosis-treatment/patient-support/patient-education-office.html">Patient Education Office</a></li></ul><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=a1c2bd05e75e" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Conversation With ChatGPT]]></title>
            <link>https://doddyh.medium.com/conversation-with-chatgpt-36a84c6375e0?source=rss-9dec98090e3f------2</link>
            <guid isPermaLink="false">https://medium.com/p/36a84c6375e0</guid>
            <category><![CDATA[chatgpt]]></category>
            <category><![CDATA[ai]]></category>
            <category><![CDATA[meaning-of-life]]></category>
            <category><![CDATA[purpose]]></category>
            <category><![CDATA[deepseek]]></category>
            <dc:creator><![CDATA[Harsha Doddihal]]></dc:creator>
            <pubDate>Thu, 30 Jan 2025 11:20:24 GMT</pubDate>
            <atom:updated>2025-01-30T11:20:24.475Z</atom:updated>
            <content:encoded><![CDATA[<p>I felt that I should share this conversation I had with ChatGPT.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*3-UMMsE_TVwNzuxo00KZ8w.png" /><figcaption>Image created with CoPilot</figcaption></figure><p>The Prompt: “How DeepSeek’s Gen AI challenge the dominance of American AI companies? How has deepseek been able to do at a fraction of cost, computing power and data? How do you forsee the future?”</p><p>DeepSeek, a Chinese artificial intelligence company founded in 2023 by Liang Wenfeng, has rapidly emerged as a formidable competitor to established American AI firms. Its flagship model, DeepSeek-R1, offers performance comparable to leading U.S. models but at a fraction of the cost and computational resources. While American companies have invested approximately $100 million and utilized tens of thousands of specialized chips to train their AI models, DeepSeek accomplished similar feats with an investment of under $6 million and just 2,000 less powerful chips. </p><p>This remarkable efficiency is attributed to DeepSeek’s innovative approaches, which were partly driven by limited access to advanced chips due to international sanctions. The company focused on optimizing programming and resource utilization, leading to significant reductions in training costs and computing power requirements. This strategy mirrors historical instances where constraints have spurred technological innovation. </p><p>The emergence of DeepSeek has significant implications for the global AI landscape. By demonstrating that high-performance AI models can be developed with reduced resources, DeepSeek challenges the dominance of American tech giants and opens opportunities for smaller companies and countries with limited budgets to participate in AI development. This development could democratize access to advanced AI technologies and foster a more diverse and competitive market. </p><p>Looking ahead, DeepSeek’s success may prompt a reevaluation of current AI development paradigms. The company’s emphasis on efficiency and open-source models could lead to broader adoption of cost-effective AI solutions, encouraging innovation across the industry. However, it also raises questions about data privacy and security, especially concerning the use of AI models developed under different regulatory frameworks. As the AI field continues to evolve, balancing innovation with ethical considerations will be crucial. </p><p>The references it provided for above:</p><ul><li><a href="https://www.thetimes.co.uk/article/china-ai-chatbot-us-tech-race-s709xjx9f?utm_source=chatgpt.com">China shocked the US in the AI race. What does it mean for the UK?</a></li><li><a href="https://www.vox.com/technology/397330/deepseek-openai-chatgpt-gemini-nvidia-china?utm_source=chatgpt.com">DeepSeek is bad for Silicon Valley. But it might be great for you.</a></li></ul><p><a href="https://www.wsj.com/articles/u-s-businesses-already-love-deepseek-1679cde2?utm_source=chatgpt.com">https://www.wsj.com/articles/u-s-businesses-already-love-deepseek-1679cde2?utm_source=chatgpt.com</a></p><p>I asked ChatGPT:”Do you anticipate your usage coming down ?”</p><p>ChatGPT: If you’re asking whether the usage of AI models like me will decrease in the future, I don’t think that’s likely in the near term. In fact, AI adoption is growing rapidly across industries, and demand for AI-driven solutions is increasing.</p><p>However, there are a few factors that could influence AI usage patterns:</p><ol><li><strong>Cost Efficiency &amp; Competition</strong> — As more companies (like DeepSeek) develop competitive AI models at lower costs, businesses might diversify their AI providers rather than relying solely on a few dominant models.</li><li><strong>Regulation &amp; Policy</strong> — Governments worldwide are considering regulations around AI usage, which could impact how freely AI models are used in different regions and industries.</li><li><strong>Advancements in Edge AI</strong> — If AI processing shifts more to local devices (phones, laptops, on-premise servers) rather than cloud-based models, usage of large-scale online AI models could become more specialized rather than general-purpose.</li><li><strong>User Habits &amp; Fatigue</strong> — While AI is useful, some users may reduce their dependence on it for certain tasks once they develop their own expertise or find alternative tools.</li></ol><p>That said, as AI continues improving in reasoning, multimodal capabilities (text, image, video, code, etc.), and personalization, I anticipate overall AI usage will keep growing, even if the way people interact with it evolves.</p><p>Me: “How can people develop expertise if they use AI for their work? Is it not contradictory?”</p><p>ChatGPT: It’s a great question, and at first glance, it may seem contradictory — how can people develop expertise if they rely on AI? However, AI can actually enhance expertise rather than replace it, depending on how it is used. Here’s how:</p><h4>1. AI as a Learning Aid, Not a Replacement</h4><p>Instead of replacing human thinking, AI can accelerate learning by providing instant feedback, explanations, and insights. For example, a programmer using AI for debugging can analyze AI’s suggestions, understand patterns, and gradually develop a deeper grasp of coding best practices.</p><h4>2. Using AI for Higher-Order Thinking</h4><p>AI is good at automating repetitive tasks and retrieving knowledge, but human expertise involves creativity, critical thinking, and judgment. Professionals who use AI effectively can focus on problem-solving, strategy, and innovation rather than just execution.</p><h4>3. AI as a Thought Partner</h4><p>Rather than just following AI-generated answers blindly, people who challenge, verify, and build upon AI responses gain deeper understanding. For instance, a lawyer using AI for legal research can critically assess the AI’s references and strengthen their legal reasoning.</p><h4>4. AI Encourages Continuous Learning</h4><p>Since AI evolves rapidly, professionals must constantly update their knowledge to stay ahead. The presence of AI forces people to engage in lifelong learning, adapt to new tools, and develop meta-skills like AI literacy.</p><h4>5. Developing Unique Human Skills</h4><p>Skills such as emotional intelligence, leadership, negotiation, and ethical decision-making remain uniquely human. AI can assist, but expertise in these areas comes from experience, human interaction, and judgment — things AI cannot fully replicate.</p><h4>The Real Danger: Passive vs. Active Use</h4><p>The real risk is passive AI usage — when people blindly accept AI outputs without questioning or understanding them. However, when AI is used actively — as a tool for exploration, critical thinking, and deeper engagement — people can still develop expertise while leveraging AI’s capabilities.</p><p>Would you agree, or do you see a stronger downside?</p><h4>Me: “I agree but I think only 3–10% of population or lesser than that will develop the expertise and challenge AI. Most of the population could become more lazy and have existential crisis! What do you think ? Will see a decline in purpose for humans ?”</h4><p>ChatGPT:</p><p>I completely understand your concern, and you’re right — only a small percentage of people may actively engage with AI in a way that enhances their expertise, while the majority might become more dependent on it without questioning or learning from it. This could have profound societal consequences, including:</p><h4>1. Increased Dependence &amp; Cognitive Decline</h4><p>If AI handles everything from decision-making to creativity, many people may stop developing critical thinking skills. Over-reliance on AI could lead to a decline in problem-solving abilities, making humans less capable of independent thought.</p><h4>2. Existential Crisis &amp; Loss of Purpose</h4><p>Work has traditionally been a major source of meaning for many people. If AI automates large portions of jobs, those who don’t find new avenues for creativity, contribution, or purpose may struggle with a sense of worthlessness. This is already a growing concern, as automation continues to reshape industries.</p><h4>3. A Wider Intelligence &amp; Productivity Gap</h4><p>Just as the internet created a knowledge gap between those who actively seek information and those who passively consume content, AI could widen the divide further. The few who learn to use AI as a tool to amplify their thinking will thrive, while many others might become passive consumers, deepening social inequalities.</p><h4>4. Devaluation of Human Creativity &amp; Effort</h4><p>If AI can generate art, music, literature, and even scientific theories, people may feel that their contributions are less valuable. This could lead to a decline in intrinsic motivation to create, explore, and push boundaries.</p><h4>5. Shift in Human Purpose &amp; Meaning</h4><p>While work has historically been a key driver of purpose, humans have also derived meaning from relationships, exploration, spirituality, and personal growth. As AI takes over labor-intensive tasks, people may be forced to redefine their purpose — perhaps by focusing on self-improvement, philosophical pursuits, or deeper human connection.</p><h4>Will Purpose Decline or Transform?</h4><p>I don’t think humanity will completely lose its sense of purpose, but there may be a turbulent transition. Throughout history, technological advancements (from the industrial revolution to the digital age) have always displaced certain jobs while creating new ones. The real challenge will be whether society can adapt quickly enough — by redefining work, education, and the meaning of contribution.</p><p>Ultimately, those who learn to use AI wisely — as a tool for augmentation rather than replacement — will likely feel more empowered rather than lost. The real question is: <strong>Can society as a whole shift toward a new paradigm of purpose before widespread disillusionment sets in?</strong></p><p>Do you think we will manage this transition well, or do you foresee a deeper crisis unfolding?</p><p>I stopped at the above reply.</p><p>What followup questions should I ask it?</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=36a84c6375e0" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Epigenetic Editing or Epi Editing]]></title>
            <link>https://doddyh.medium.com/epigenetic-editing-or-epi-editing-087451a59cef?source=rss-9dec98090e3f------2</link>
            <guid isPermaLink="false">https://medium.com/p/087451a59cef</guid>
            <category><![CDATA[genetic-medicine]]></category>
            <category><![CDATA[innovation]]></category>
            <category><![CDATA[healthcare]]></category>
            <category><![CDATA[biotech]]></category>
            <category><![CDATA[epigenetics]]></category>
            <dc:creator><![CDATA[Harsha Doddihal]]></dc:creator>
            <pubDate>Mon, 13 Jan 2025 11:21:02 GMT</pubDate>
            <atom:updated>2025-01-13T11:21:02.212Z</atom:updated>
            <content:encoded><![CDATA[<p>When a life science company gets Series B funding of $ 175M, it is time to notice, celebrate and understand.</p><p>What is Epigenetics and Epigenetic Editing?</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*9gznAymh7tygk3T8dIU30g.png" /></figure><p>We all know that we get our DNA from our parents and inherit certain traits. We are not exactly like them (some of you would be saying “thank god or science for that”), because the DNA is unique and we are not like our brothers or sisters. Fraternal twins have different DNA but identical twins (monozygotic twins) have same DNA or so…The phenotypic differences in identical twins is most often due to “Epigenetics”.</p><p>Gene editing involves inserting, deleting, modifying, or replacing specific DNA sequences in the genome. The CRISPR-Cas9 system, often referred to as “genetic scissors,” is one of the most significant gene editing tools. It was discovered by Jennifer Doudna and Emmanuelle Charpentier. Their groundbreaking work allows scientists to edit DNA with unprecedented precision, opening up remarkable possibilities in biology and medicine. They were awarded the 2020 Nobel Prize in Chemistry.</p><p>During COVID we also got to know mRNA and RNA based therapeutics.</p><p>If the DNA sequence gets altered, we call it mutation. If there are changes in the DNA without its sequence getting altered, it is Epigenetics. Right from embryonic stage, epigenetics is at play. Which genes will get expressed and which will not, is done by epigenetics.</p><h4>“<a href="https://www.frontiersin.org/journals/pediatrics/articles/10.3389/fped.2017.00178/full"><em>The term “epigenetics,” which literally means “on top of genetics,” defines a variety of processes that cause mitotically and meiotically heritable changes in gene expression without modifying the deoxyribonucleic acid (DNA) sequence; particularly, DNA methylation, histone modification, and non-coding RNA are the main mechanisms underlying epigenetic modifications.”</em></a></h4><p>Maternal nutrition during pregnancy influences epigenetic modifications in the developing fetus, with lasting impacts on gene expression and long-term health outcomes.</p><p>So there is a chance that we are influenced by what our grandparents ate or did! Phew !</p><p>Epigenetic inheritance from grandparents can significantly influence their grandchildren’s health and traits. Several studies have shown that grandparental diet and experiences can affect subsequent generations through epigenetic mechanisms:</p><ol><li>Överkalix studies: Research on a Swedish population revealed that food availability during a grandfather’s childhood was associated with mortality rates and diabetes risk in their grandchildren.</li></ol><p>Specifically:</p><ul><li>Paternal grandfather’s food supply correlated with grandson mortality</li><li>Paternal grandmother’s food supply correlated with granddaughter mortality</li></ul><p>2. Dutch Hunger Winter study: Children conceived during the 1944–1945 famine in the Netherlands showed an elevated risk of metabolic disorders, obesity, diabetes, and cardiovascular diseases.</p><p>3. Holocaust survivor study: Descendants of Holocaust survivors exhibited epigenetic changes related to stress response</p><p>It’s important to note that while animal studies provide strong evidence for transgenerational epigenetic inheritance, human evidence is more limited due to the complexity of controlling for genetic and environmental factors across generations.</p><h3><strong>“Potential of Epi-Editing”</strong></h3><p>Epigentic editing wold involve modifying “methylation” or “histone mdoficiation” or “altering non-coding RNA”.</p><p>The journey began in the early 2000s at the University of Groningen, where Marianne Rots and her team pioneered the first targeted epigenetic editors. UC San Francisco’s Jonathan Weissman and MIT’s Rudolf Jaenisch later made groundbreaking contributions with their work on CRISPR-based epigenetic regulators.</p><p>Other universities instrumental in developing epigenetic editing technology:</p><p>1. Duke University: Charlie Gersbach’s lab at Duke spawned Tune Therapeutics.</p><p>2. University of Amsterdam: Part of the Epi-Guide-Edit consortium developing epigenetic reprogramming tools.</p><p>3. Leiden University: Another key member of the Epi-Guide-Edit consortium.</p><p>4. Wageningen University: Contributing to both biomedical and biotechnological applications of epigenetic editing.</p><p><strong>Companies Working on Epigenetic Editing</strong></p><p>Several companies are at the forefront of epigenetic editing research and development:</p><p>1. Chroma Medicine: Based in Massachusetts, Chroma Medicine has developed programmable epigenetic editors that target genes and control chromatin conformation. They have had total funding of $ 260M. They acquired Epsilen Bio, a Milan based company. Their technology focuses on:</p><p>a. Controlling gene expression by changing chromatin shape</p><p>b. Developing single-dose genomic medicines</p><p>c. Creating lasting changes that persist through cell division</p><p>They are targeting infections, LDL cholesterol level genes and probably cancer.</p><p>2. Epic Bio: Located in California, Epic Bio uses its Gene Expression Modulation System (GEMS) platform to control the epigenome without making permanent DNA edits. Epic Bio holds an exclusive license to CasMINI, the smallest known Cas protein, enabling in vivo delivery via AAV vectors to various target organs. The company’s lead program in facioscapulohumeral muscular dystrophy (FSHD). Epic Bio is also developing therapies for heterozygous familial hypercholesterolemia (HeFH), alpha-1 antitrypsin deficiency (A1AD), and retinitis pigmentosa (RP4 and RP11)</p><p>3. Tune Therapeutics: Spun out of Duke University, Tune Therapeutics is developing epigenetic editing therapies. Tune is also focusing on Hepatitis B and LDL cholesterol gene (PCSK9 gene).</p><p>4. Omega Therapeutics: This company is working on epigenetic editing applications in oncology. Omega’s lead program, OTX-2002, targets hepatocellular carcinoma (HCC). The company has raised $211 million over 4 rounds. Omega Therapeutics’ approach aims to address previously undruggable targets and has potential applications in oncology, regenerative medicine, and multigenic diseases including immunologic and cardiometabolic conditions</p><p><strong>Clinical Development and Progress</strong></p><p>Several molecules are in various stages of clinical development:</p><p>1. OTX-2002: Developed by Omega Therapeutics, this molecule is in Phase I/II clinical trials for liver cancer.</p><p>2. EPI-321: Epic Bio’s lead candidate for facioscapulohumeral muscular dystrophy (FSHD) is undergoing Investigational New Drug (IND)-enabling studies.</p><p>3. Tune Therapeutics’ HBV therapy: The company plans to file a Clinical Trial Application soon for their epigenetic silencer targeting hepatitis B.</p><p><strong>To wrap it up</strong></p><p>Exciting times ahead. Maybe we can undo what our grandparents did to us?</p><p>The money is defintely flowing there. <a href="https://www.altoslabs.com/">Altos Lab</a>s is funded with $3 billion, <a href="https://www.newlimit.com/">NewLimit</a> is backed by Coinbase CEO Brian Armstrong, and <a href="https://www.retro.bio/">Retro Biosciences</a>, which is funded entirely by OpenAI CEO Sam Altman.</p><p>#Biotech #GeneticMedicine #Epigenetics #Innovation #Healthcare</p><p>References:</p><ul><li><a href="https://www.nature.com/articles/s41588-024-01706-w">Systematic epigenome editing captures the context-dependent instructive function of chromatin modifications - Nature Genetics</a></li><li><a href="https://www.nature.com/articles/s41598-023-28896-3">Maternal diet induces persistent DNA methylation changes in the muscle of beef calves - Scientific Reports</a></li><li><a href="https://www.mcgill.ca/oss/article/general-science/identical-twins-are-not-identical">Identical Twins Are Not Identical</a></li><li><a href="https://www.u-tokyo.ac.jp/focus/en/features/z1304_00241.html">Why are there differences between identical twins? | The University of Tokyo</a></li><li><a href="https://www.frontiersin.org/journals/pediatrics/articles/10.3389/fped.2017.00178/full">Frontiers | Epigenetic Matters: The Link between Early Nutrition, Microbiome, and Long-term Health Development</a></li><li><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC9377665/">CRISPR-Cas9: A History of Its Discovery and Ethical Considerations of Its Use in Genome Editing</a></li><li><a href="https://www.labiotech.eu/best-biotech/epigenetics-companies/">Six epigenetics companies making strides in 2024</a></li></ul><p>AI tools- Claude, Perplexity, ChatGPT.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=087451a59cef" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[China’s Leapfrog in New Drug Development]]></title>
            <link>https://doddyh.medium.com/chinas-leapfrog-in-new-drug-development-6e8d12237360?source=rss-9dec98090e3f------2</link>
            <guid isPermaLink="false">https://medium.com/p/6e8d12237360</guid>
            <category><![CDATA[innovation]]></category>
            <category><![CDATA[china]]></category>
            <category><![CDATA[drug-discovery]]></category>
            <category><![CDATA[global-health]]></category>
            <category><![CDATA[biotech]]></category>
            <dc:creator><![CDATA[Harsha Doddihal]]></dc:creator>
            <pubDate>Thu, 19 Dec 2024 00:28:36 GMT</pubDate>
            <atom:updated>2024-12-19T08:34:03.244Z</atom:updated>
            <content:encoded><![CDATA[<p>China has made significant strides in drug development over the past two decades, transitioning from being a producer of generic drugs to a global player in innovative therapeutics. This transformation is often described as a <strong>leapfrog</strong>, bypassing traditional development stages by leveraging global best practices and tailoring them to China’s unique strengths.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*B1JAvq6y-cJoOsXNRyckFA.png" /><figcaption>Image Created by Dall E 3</figcaption></figure><p>The Model Used by China</p><p>China’s success in leapfrogging is attributed to a hybrid model, combining strategies from both the US biotech ecosystem and tailored state-led initiatives:</p><h4>a. Government Support and Policy Reform</h4><p><strong>Regulatory Overhaul:</strong></p><ul><li>The China Food and Drug Administration (CFDA), rebranded as the National Medical Products Administration (NMPA), aligned its standards with those of the FDA/EMA.</li><li>Accelerated approval pathways, such as the Priority Review<strong> and </strong>Breakthrough Therapy Designation, were implemented to fast-track innovative drugs.</li></ul><p><strong>Supportive Policies:</strong></p><ul><li>Government initiatives like Made in China 2025 and the Healthy China 2030 plan incentivize innovation in biotech and pharmaceuticals.</li><li>Substantial R&amp;D tax incentives and subsidies are provided to biotech startups.</li></ul><h4>Leveraging Talent and Global Integration</h4><p><strong>Return of Talent (“Sea Turtles”):</strong></p><ul><li>Thousands of Chinese scientists trained in the US or Europe have returned to China, bringing expertise in drug discovery, clinical trials, and commercialization.</li><li>Examples include founders of leading companies like BeiGene and Innovent Biologics.</li></ul><p><strong>Global Partnerships:</strong></p><ul><li>Chinese companies partner with Western firms for co-development, licensing, and clinical trials</li></ul><ol><li>BeiGene and Novartis: A $2.2 billion deal for Novartis to in-license BeiGene’s PD-1 inhibitor tislelizumab for markets outside China (later this partnership fell through).</li><li>Legend Biotech and Johnson &amp; Johnson: Collaboration resulting in Carvykti, a treatment for bone marrow cancer, launched in the US in 2022</li><li>MediLink Therapeutics and Roche: A partnership worth over $1 billion for Roche to develop MediLink’s solid tumor treatment</li><li>Gracell Biotechnologies and AstraZeneca: AstraZeneca acquired Gracell, a Chinese CAR-T cell therapies company, for $1.2 billion</li><li>Keyuan Pharma (Shanghai Pharma subsidiary) and Pfizer: Partnership to distribute and promote Pfizer’s pneumococcal vaccine Prevenar 13 in China</li><li>CanSino Biologics and AstraZeneca: Agreement to produce potential mRNA vaccines.</li><li>Eli Lilly and Innovent’s collaboration on sintilimab.</li><li>Hengrui Medicine and Incyte: A deal potentially worth up to $795 million for out-licensing rights to Hengrui’s anti-PD-1 monoclonal antibody candidate outside Greater China</li><li>CellOrigin Biotech and Qilu Pharmaceutical: Collaboration to develop, manufacture, and commercialize iPSC-derived Chimeric Antigen Receptor Macrophages for cancer immunotherapy</li></ol><h4>c. Capital and Investment</h4><p><strong>Venture Capital and IPOs:</strong></p><ul><li>A robust domestic and global venture capital system supports biotech startups. The Hong Kong Stock Exchange (HKEX) introduced a Chapter 18A rule in 2018, allowing pre-revenue biotech companies to list publicly.</li><li>US-based Nasdaq listings by Chinese biotech firms also provide significant capital inflows.</li></ul><h4>d. Focus on Biosimilars and Biologics</h4><ul><li>While developing novel drugs, China leveraged its strength in producing biosimilars (cheaper versions of biologic drugs) as an entry point into global markets.</li><li>China initiated its biosimilar development later than the EU, US, and Japan. In 2015, China’s National Medical Products Administration (NMPA) issued technical guidelines for biosimilar development and evaluation. Unlike the US and EU, biosimilars in China are not assigned to a separate abbreviated approval pathway. They are subject to the same approval pathway as new drugs. For analytical and non-clinical studies, China allows reference products approved in China or elsewhere. However, for clinical studies, the reference product must be approved in China. China’s biosimilar market has grown rapidly, with a 25–30% CAGR over the past decade. By the end of 2019, China had 391 biosimilar drugs in the R&amp;D pipeline, the highest number globally</li></ul><h4>e. Infrastructure Development</h4><ul><li>Establishment of biotech clusters like the Zhangjiang Hi-Tech Park in Shanghai and the Shenzhen-Hong Kong Biotech Corridor provides ecosystems for innovation and manufacturing.</li></ul><h4>Chinese biotech companies have developed several innovative drugs in recent years</h4><ol><li>Glumetinib (Haihe Biopharma): A first-in-class drug approved in 2023 for treating mild to moderate COVID-19 symptoms</li><li>Fruquintinib (HUTCHMED): Approved by the FDA in 2023 for metastatic colorectal cancer treatment</li><li>Toripalimab (Loqtorzi): The first FDA-approved drug for nasopharyngeal cancer, developed by a Chinese company</li><li>Zanubrutinib: A cancer drug developed by BeiGene, demonstrating China’s growing competitiveness in securing core patents</li><li>LM-299: An anticancer antibody developed by LaNova Medicines, licensed to Merck &amp; Co. in a deal worth up to $3.3 billion</li><li>CS1001: China’s first fully human anti-PD-L1 monoclonal antibody approved for clinical development, created by CStone Pharma</li><li>CAR-GPC3: The world’s first CAR-T cell therapy for advanced hepatocellular carcinoma, developed by CARsgen Therapeutics</li><li>LCAR-B38M: An anti-BCMA CAR-T therapy for multiple myeloma by Legend Biotech, showing high efficacy in early trials</li><li>Disitamab vedotin (RC48): An antibody-drug conjugate by RemeGen, conditionally approved in China for gastric cancer and granted FDA breakthrough therapy status for urothelial cancer.</li><li>MDR-001: An AI-driven small molecule medication targeting obesity and type 2 diabetes, developed by MindRank.</li></ol><p>These innovations span various therapeutic areas, including oncology, infectious diseases, and metabolic disorders, demonstrating China’s progress in developing first-in-class and best-in-class drugs.</p><h4>What Can Other Developing Countries Learn from China?</h4><ol><li><strong>Government-Led Support:</strong></li></ol><p>Strong government policies and infrastructure investments are critical. Other countries can adopt clear regulatory frameworks, tax incentives, and public-private partnerships to attract investment and foster innovation.</p><p><strong>2. Human Capital Development:</strong></p><p>Training local talent and encouraging the return of diaspora scientists can help transfer expertise in high-tech fields.</p><p><strong>3. Global Collaboration:</strong></p><p>Partnering with established global companies for licensing, co-development, and technology transfer accelerates progress while bridging knowledge gaps.</p><p><strong>4. Focus on Biosimilars:</strong></p><p>Developing countries can focus on biosimilars as an entry point into biotechnology while building capacity for innovative drugs.</p><p><strong>5</strong>. <strong>Capital Market Reform:</strong></p><p>Facilitating access to domestic and international capital markets for pre-revenue biotech companies can provide critical funding at early stages.</p><p>Reference: Aritcle written with inputs/ content from ChatGPT and Perplexity</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=6e8d12237360" width="1" height="1" alt="">]]></content:encoded>
        </item>
    </channel>
</rss>